AKR1B10: A potential target for cancer therapy |
| |
| Authors: | Xuyu Zu Ruilan Yan Duan-Fang Liao Deliang Cao |
| |
| Institution: | a Division of Pharmacoproteomics, Institute of Pharmacy & Pharmacology, University of South China, School of Life Science and Technology. 28 Changshengxi Road, Hengyang, Hunan 421001, PR China
b Department of Medical Microbiology, Immunology, & Cell Biology, and SimmonsCooper Cancer Institute, Southern Illinois University School of Medicine. 913 N. Rutledge Street, Springfield, IL, USA 62702 |
| |
| Abstract: | Aldo-keto reductase family 1 B10 (AKR1B10, also designated aldose reductase-like-1, ARL-1) is a novel protein identified from human hepatocellular carcinoma (HCC). This protein belongs to aldo-keto reductase superfamily, a group of proteins implicated in intracellular detoxification, cell carcinogenesis, and cancer therapeutics. AKR1B10 is primarily expressed in the colon and small intestine with low levels in the liver, thymus, prostate, and testis but overexpressed in the liver and lung cancer, making it a potential cancer diagnostic and/or prognostic marker. AKR1B10 could reduce retinals to retinols eliminating intracellular retinoic acid, a signaling molecule regulating cell proliferation and differentiation. AKR1B10 may impact the carcinogenesis process through controlling retinoic acid signaling. |
| |
| Keywords: | AKR1B10 Retinoic acid metabolism Cancer therapy |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
